Boehringer Ingelheim and Lilly announced that the U.S. prescribing information for Jentadueto (linagliptin and metformin HCl) now includes new clinical data from a prospective 24-week Phase 4 trial. Jentadueto is a combination of a dipeptidyl peptidase-4 inhibitor and a biguanide indicated as adjunct to diet and exercise in type 2 diabetes.

The randomized, double-blind study evaluated the efficacy and safety of linagliptin 5mg daily in combination with metformin 1500–2000mg daily (n=159) vs. linagliptin 5mg daily (n=157) alone in treatment-naive adults with type 2 diabetes with high baseline A1c (8.5–12%). The primary endpoint was defined as change from baseline in A1c after 24 weeks.

RELATED: Tradjenta, Jentadueto Update Regarding Pancreatitis Risk

The data showed initial therapy with the combination of linagliptin and metformin reduced A1c levels by 2.9% vs. 2.0% for linagliptin alone. Also, there was a statistically significant mean difference in A1C between the combination and linagliptin alone of -0.84%.

These findings along with key secondary endpoint results have been added to the “Clinical Studies” section of the U.S. prescribing information.

For more information call (800) 243-0127 or visit